• RWE shows high concordance with RCTs for efficacy outcomes, supporting its use in regulatory decisions.
• Safety outcomes from RWE have lower concordance, highlighting the need for robust pharmacovigilance.
• Prospective registry-based RWE is more reliable than retrospective database studies.
• Integration of RWE can accelerate drug approval and improve patient access to therapies.